Ventripoint
September 15, 2021
Ventripoint Provides Update on Clinical Studies
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has provided an update on clinical studies using the VMS+ 3.0.Ventripoint Overview: A Revolutionary Way to View and Analyze the HeartVentripoint is an industry leader in the application of ultrasound AI…...
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that it has filed its interim unaudited Financial Statements and Management Discussion and Analysis (MD&A) for the second quarter, ending June 30, 2021. These filings can be…...
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has filed an international patent application under the Patent Cooperation Treaty (PCT) to protect Ventripoint’s recent novel improvements to its cardiac measurement technology. Ventripoint is a pioneer in application of artificial…...
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to provide this update on its financial status and the exercises of warrants and options since the last update (see NR March 3, 2021).Since the last update, the Company…...
May 4, 2021
Ventripoint Receives Government Funding to Advance Development of Next Generation of VMS+
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is excited to announce that it is receiving advisory services and research and development funding of up to $120,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC…...
April 27, 2021
Ventripoint Collaborates with GE Healthcare to Bring More Functionality to its Cardiac Ultrasound Devices
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) announces the Company has entered into a collaboration with GE Healthcare.Ventripoint has been added as an innovator under GE Healthcare’s Edison Developer Program, which helps healthcare providers gain access to market-ready…...
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) attended the 23rd Annual Canadian Echo Weekend – 2021 Digital Edition, which was organized by the Canadian Society of Echocardiography (CSE).Ventripoint participated as a sponsor for this year’s conference and received…...
April 19, 2021
Ventripoint Extends Patent Portfolio with Foundational U.S. Provisional Patent Filing of Heart Motion Tracking Technology
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) has filed a U.S. provisional patent application for its novel cardiac measurement approach.This new measurement technique provides cardiologists with additional and more precise information about the function of the heart through…...
April 15, 2021
Ventripoint Announces Sponsorship for the 2021 Canadian Society of Echocardiography Weekend Conference
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce its sponsorship of the 2021 Canadian Society of Echocardiography (CSE) Virtual Echo Weekend Conference to be held this weekend on April 17-18, 2021.The CSE strives to promote…...
April 13, 2021
Ventripoint Diagnostics Begins Publication of Case Studies Showing Meritorious Use of the VMS Heart Analysis System
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has published its first case study of the meritorious use of the Ventripoint VMS whole-heart analysis system (https://www.ventripoint.com/whitepapers-case-studies) in routine clinical practice.Dr. Gregory Skinner at East Midlands Congenital Heart Centre, Leicester,…...